Ladenburg Thalmann Downgrades Marinus Pharmaceuticals (MRNS) to Neutral
Tweet
Share
E-mailGet Alerts MRNS Hot Sheet
Price: $0.55 --0%
Rating Summary:
6 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Ladenburg Thalmann analyst Michael Higgins downgraded Marinus Pharmaceuticals (NASDAQ: MRNS) from Buy to Neutral.
For an analyst ratings summary and ratings history on Marinus Pharmaceuticals click here. For more ratings news on Marinus Pharmaceuticals click here.
Shares of Marinus Pharmaceuticals closed at $1.18 yesterday.
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- JPMorgan Downgrades HomeCo Daily Needs REIT (HDN:AU) to Neutral
- Barclays Downgrades Murphy Oil Corp. (MUR) to Underweight
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
